<DOC>
	<DOC>NCT02943720</DOC>
	<brief_summary>A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis</brief_summary>
	<brief_title>ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Adult subjects 18 to 65 yrs old, male or female moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons positive Skin Prick Test (SPT) to birch pollen extract positive specific IgE CAP to Bet v1. persistent noncontrolled asthma (Forced Expiratory Volume, FEV1 &lt; 85% of predicted), previous specific immunotherapy (SIT) to tree pollens, previous SIT to any allergen within 5 years, previous history of severe anaphylactic reaction, perennial allergic Rhinitis/Rhinoconjunctivitis, other disorder possibly influencing the trial outcomes, pregnancy, any severely debilitating disease, primary or secondary immunodeficiency or treatment with immunosuppressor drugs within one month prior to randomization (oral steroids, other immunosuppressors).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>